Pfizer R&D Executive Mikael Dolsten Announces Resignation
Tuesday, 9 July 2024, 11:03
Pfizer R&D Executive Mikael Dolsten Resigns
Pfizer's head of Research and Development, Mikael Dolsten, is set to depart from the company, causing ripples in the industry. This move could signal significant shifts in Pfizer's strategic focus and innovation efforts in the pharmaceutical sector. Dolsten's resignation may impact ongoing projects and future research initiatives.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.